In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study

Saulius K Girnius,Habte A Yimer,Stephen J Noga,Sudhir Manda,Roger M Lyons,Kimberly Bogard,Presley Whidden,Dasha Cherepanov,Vickie Lu,Jack Aiello,Joshua R Richter,Robert M Rifkin

doi:10.1182/blood-2020-140482

In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study

Saulius K Girnius, Habte A Yimer + Show 10 more

Open Access

https://doi.org/10.1182/blood-2020-140482

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 1

Affiliation: TriHealth, Texas Oncology, Takeda (United States), Millennium Engineering and Integration (United States), Arizona Oncology, Empowerment Program, Icahn School of Medicine at Mount Sinai, Rocky Mountain Cancer Centers

#Duration Of Therapy #Speakers Bureau + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study

Full Text